Abstract: The invention is based on the discovery that adults having a genotype comprising a hemoglobin .alpha.-gene deletion are significantly more likely to be hypertensive than adults having a normal (.alpha..alpha./.alpha..alpha.) gentoype. The invention provides an improved method for determining a human subject's genotype at the .alpha.-gene loci; a method of screening a human subject for an increased potential of developing hypertension and other blood-related disorders; and provides an apparatus/kit for screening a human subject for a risk of developing hypertension and other blood-related disorders.
Abstract: Hypoxia selective cytotoxins having the structural formula ##STR1## wherein D, E, F and G, independently, are carbon or nitrogen, with the proviso that three or more of D, E, F and G are carbon; R.sub.1 and R.sub.2, independently, are selected from the group consisting of methyl, halo, hydro, trifluoromethyl, methoxy, cyano, and methylsulfo; R.sub.3 and R.sub.4, independently, are selected from the group consisting of methyl, ethyl, phenyl, naphthyl, tertiary butyl, halo, halomethylene, hydro, trifluoromethyl, cyano and methylsulfo, or R.sub.3 and R.sub.4 taken together are a substituted or unsubstituted five or six-membered nonaromatic ring system; n is an integer 1 through 5; X is carbon or nitrogen; and Z is a physiologically acceptable anion, are disclosed. The compounds are useful as radiosensitizers or chemosensitizers, especially in the treatment of cancer patients.
Type:
Grant
Filed:
December 21, 1994
Date of Patent:
February 11, 1997
Assignee:
Evanston Hospital Corporation
Inventors:
Maria V. Papadopoulou-Rosenzweig, William D. Bloomer